Osaka-Based Reve21 Obtains Hair Loss Device Rights From Sweden's Dignitana
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Reve21 signed an agreement with Swedish firm Dignitana and obtained exclusive market rights for DigniCap, a scalp cooling device to prevent hair loss in cancer patients undergoing chemotherapy. Composed of a cooling unit with a control panel and a silicon cap, the device is designed to treat two patients simultaneously. DigniCap works to prevent hair loss through cooling scalp and slowing blood flow to follicles. A clinical study conducted by the company shows that among 2,249 patients with breast and ovarian cancers, 1,922 people did not need wigs after receiving the treatment. DigniCap is not yet approved in Japan and Reve21 looks to start Japanese trials within the year with a target market launch in 2011. (Click here for more - Japanese language